# OnCo record linperlisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/linperlisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "linperlisib" ;
  schema:name "Linperlisib"@en ;
  schema:alternateName "Yinlijia"@en ;
  schema:description "Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines."@en ;
  schema:url <https://onco.cc/drugs/linperlisib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=YY-20394> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Oral PI3K-delta inhibitor" ;
  onco:approval "CN 2022: Relapsed or refractory follicular lymphoma after two or more lines, conditional" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:companies <https://onco.cc/companies/shanghai-yingli/> ;
  onco:trials <https://onco.cc/trials/nct06224257/>, <https://onco.cc/trials/nct04379167/> .